Dickinson Andrew D 4

4 · GILEAD SCIENCES, INC. · Filed Mar 12, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

Gilead CFO Andrew Dickinson Exercises Options, Receives RSUs

What Happened

Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), exercised stock options on 2026-03-10 to acquire 6,469 shares. To cover tax withholding, 3,147 shares were surrendered/disposed at $148.56 per share, totaling $467,518. On the same date he was granted restricted stock units (RSUs) totaling 45,470 units (9,590 + 35,880), recorded as derivative awards in the filing.

Key Details

Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (not a late filing).
Option exercise: 6,469 shares acquired (transaction code M).
Tax withholding/payment: 3,147 shares disposed at $148.56 each; proceeds/withholding = $467,518 (transaction code F).
Grants: 9,590 RSUs and 35,880 RSUs awarded (transaction code A); grant value recorded as $0.00 for the 35,880 RSUs in the filing (the awards are contingent/derivative).
Vesting: RSUs and stock options follow a four‑year vesting schedule — 25% at the first anniversary, then 6.25% quarterly thereafter (per footnotes).
Shares owned after the transaction: not specified in the provided filing details.
No 10b5-1 plan or other sale plan is referenced in the provided data.

Context

The filing shows an option exercise combined with share withholding to satisfy tax obligations (common “net settlement”/withholding treatment), not an open‑market sale of shares for personal cash. The RSU grants are compensation awards that vest over time per the four‑year schedule; such grants are routine executive compensation and do not by themselves indicate a change in market view.

Form 4

Period: 2026-03-10

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-10+6,469→ 185,338 total
Tax Payment
Common Stock
2026-03-10$148.56/sh−3,147$467,518→ 182,191 total
Exercise/Conversion
Restricted Stock Unit
[F1][F2]
2026-03-10−6,469→ 21,057 total
→ Common Stock (6,469 underlying)
Award
Restricted Stock Unit
[F1][F2]
2026-03-10+9,590→ 30,647 total
→ Common Stock (9,590 underlying)
Award
Non-qualified Stock Option (Right to Buy)
[F3]
2026-03-10+35,880→ 35,880 total
Exercise: $148.56Exp: 2036-03-10→ Common Stock (35,880 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
[F2]The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
[F3]The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Signature

/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson|2026-03-12

1 file